Wallgren's Disease

Wallgren's disease: Understanding and perspectives

Wallgren's disease, also known as Wallgren-Westergren disease, named after the Swedish pediatrician A. J. Wallgren (1889-1973), is a rare genetic disorder that affects the nervous system and muscles. The disease was first described by Wallgren in 1940 and has since attracted the attention of the medical community due to its complexity and health implications for patients.

Wallgren's disease belongs to a group of neuromuscular diseases that are characterized by impaired muscle development and function. This hereditary disease runs in families according to the principle of autosomal recessive inheritance, which means that for the disease to develop there must be two abnormal genes, one inherited from each parent.

The main symptoms of Wallgren's disease are muscle weakness, decreased muscle tone and problems with coordination of movements. These symptoms may begin in early childhood and worsen over time. Wallgren's disease may also be accompanied by speech impediments, psychomotor retardation, and breathing problems.

The diagnosis of Wallgren's disease is usually based on clinical manifestations and genetic testing. Although there is no specific treatment for this disease, symptomatic treatment and rehabilitation measures can help improve the quality of life of patients. Physical therapy, occupational therapy, and speech therapy may be included in a comprehensive approach to disease management.

Although Wallgren's disease is a rare disorder, research in this area continues. Much research is aimed at finding a deeper understanding of the molecular mechanisms underlying this disease and developing new therapeutic approaches.

Thanks to progress in genetic research and the development of new technologies such as gene therapy and genome editing, new prospects are opening up in the treatment of Wallgren's disease. These advanced treatments may offer potential approaches to correct genetic abnormalities associated with this disorder and improve the lives of patients.

In conclusion, Wallgren's disease is a rare genetic disorder that causes muscle weakness and problems with motor coordination. This hereditary disease requires further research and development of new therapeutic approaches. Modern genetic research and advanced treatments such as gene therapy may offer hope for better management and treatment of Wallgren's disease in the future.

Wallgreni's disease is an inflammation of the anterior end of the inferior turbinate and the middle cranial fossa. It occurs in children and rarely in adults. A one-sided process is more often observed.

The main etiological factor is considered to be staphylococcus, Haemophilus influenzae and pneumococcal infections, which is confirmed by bacteriological examination (bacterioscopy) of nasal discharge, culture of mucus and rinsing water on nutrient media; repeated puncture. Treatment is carried out with penicillin, sofradex, tobradox. In the remission phase, exercise therapy, massage, and physiotherapeutic treatment are prescribed. Sanatorium-resort treatment is carried out in specialized pediatric dispensaries.